GlassScriptPhysician profile
Mary Ellen Monaco
NPI 1972607497
$17,879.24
in general payments reported to CMS, 2019-2025
64 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $1,986 · 2021: $3,151 · 2022: $3,217 · 2023: $2,699 · 2024: $2,868 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,812.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,796.56 | 2021-2025 | |
| Lilly USA, LLC | $1,659.20 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $1,531.24 | 2019-2025 | |
| Eisai INC. | $920.90 | 2019-2025 | |
| Lundbeck LLC | $778.37 | 2021-2025 | Vyepti |
| Sk Life Science, INC. | $754.90 | 2020-2024 | Xcopri |
| Amneal Pharmaceuticals LLC | $705.94 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Janssen Pharmaceuticals, INC | $679.45 | 2021-2023 | |
| Pfizer INC. | $632.36 | 2019-2025 | |
| Kyowa Kirin, INC. | $588.43 | 2019-2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $544.14 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $436.75 | 2019-2022 | |
| Allergan, INC. | $429.02 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $414.20 | 2019-2022 | |
| Biogen, INC. | $357.08 | 2019-2025 | Vumerity, Skyclarys, Tysabri |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Monaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.